spacer
home > ebr > summer 2017 > upcycling genomics
PUBLICATIONS
European Biopharmaceutical Review

Upcycling Genomics

Gene therapies have taken centre stage in the medical field and interest is growing rapidly. For the first time, people can hope for a true cure of heritable disabilities by accessing a patient’s genome, as opposed to being treated only symptomatically, and any acquired pathologies with genetic elements are part of this development. HIV, for example, ‘hides’ in blood cells by integrating into the host’s genome, making it nearly impossible to remove from the system without genetic means. Asthma, arthritis, hypertension and many forms of cancers are in part caused by environmental factors that throw our genetic or epi-genetic makeup out of whack.

Of course, the application of genetic tools to patients is a controversial issue, and the backlash of early trials gone wrong in the 1990s severely dampened the whole, a setback that would be felt for over 10 years in the research community. With the number of clinical studies slumping and little growth for a decade, the concurrent rise of improved gene tools, paired with a much deeper understanding of the mechanisms underlying gene delivery, prepared a veritable rebirth of this field.

Following the rise of CRISPR/Cas9 technologies, the number of therapeutic strategies has become as plentiful as the range of human afflictions. This new shift towards gene therapy brings a measurable need for the optimisation of gene delivery strategies to enable practitioners to better transport their candidate constructs in a more targeted therapeutic context. While systemic applications favour the development of adeno-associated virus vector systems, highly efficient lentiviral vectors stand out as the system of choice for ex vivo therapies of hematopoietic cells (HCs) and hematopoietic stem cells (HSCs).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Dr Franziska C Ruf is Senior Key Accounts Manager at SIRION Biotech with strong experience in molecular and cellular biology and her immunologic and hematopoietic background. Franziska worked as Project Coordinator and a Post-Doctoral Researcher in the Department of Hematology and Oncology at Klinikum rechts der Isar, Technical University Munich, Germany, where she also received her PhD in the Laboratory of Stem Cell Physiology.
spacer
Dr Franziska C Ruf
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Arcis Biotechnology appointments Professor Steve Howell as Non-Executive Chairman

Daresbury, UK, 24 July 2019: Arcis Biotechnology (“Arcis”), the nucleic acid sample preparation solution provider, today announced it has appointed Professor Steve Howell as Non-Executive Chairman of its Board of Directors. Steve takes over the position from Paul Foulger, who was serving as Chairman on an interim basis on behalf of the Board.
More info >>

White Papers

Planning the Execution of a Viral Clearance Study

Eurofins BioPharma Product Testing

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
More info >>

 
Industry Events

BIO-Europe® 2019 - 25th Annual International Partnering Conference

11-13 November 2019, Hamburg, Germany

The 25th annual BIO-Europe® event is the largest biotechnology partnering conference held in Europe. Over 4,350 global decision makers from biotechnology, pharma and finance annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. Business development executives and dealmakers consider BIO-Europe a must-attend event and an effective business strategy enabling them to meet and present to numerous potential partners. BIO-Europe features the industry’s most advanced web-based partnering system enabling delegates from all parts of the biotechnology value chain to quickly identify, engage and enter into strategic relationships that drive their business successfully forward. BIO-Europe's world-class workshops, panels and active exhibition along with thousands of prescheduled one-to-one meetings make this event an unrivaled forum for companies across the biotech value chain to meet and do business. Learn more.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement